ClinicalTrials.gg
RecruitingNCT06561308Updated Jul 29, 2026

Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

A Phase 2 interventional study of Camrelizumab and Carboplatin in Endometrioid Endometrial Cancer, sponsored by Women's Hospital School Of Medicine Zhejiang University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Women's Hospital School Of Medicine Zhejiang University · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing carboplatin in Endometrial Neoplasms — 4 open to participants now, 9 under way, 3 of them phase 3. Carboplatin · Endometrial Neoplasms.

Planned enrollment
14th of 24
39 · median 41
Started
2025
with 1 other
Phase 2
17 of 26
2 open now
Registered
24th of 26
by date

Among the 26 studies testing carboplatin in Endometrial Neoplasms, this one is the 14th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2025, is one of 17 in phase 2, and was the 24th registered.

Endometrial Neoplasms

1,426 studies on the registry are indexed under Endometrial Neoplasms; 471 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

4 of the 26 studies testing carboplatin in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 357 Endometrial Neoplasms studies recruiting now, 267 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing carboplatin in Endometrial Neoplasms, or all of them as a file.
02

Study summary

Exploring the therapeutic effect of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab on advanced stage III-IV endometrial cancer

Read the detailed description

Conduct domestic multicenter, prospective phase II single arm clinical trials to answer the following questions:

  1. Evaluate the impact of neoadjuvant chemotherapy combined with camrelizumab on the remission rate, surgical complications, and surgical resection rate of advanced stage III-IV endometrial cancer;
  2. Evaluate the effect of of neoadjuvant chemotherapy combined with camrelizumab on the survival of patients with advanced III-IV endometrial cancer;
  3. Exploring the changes in tumor local immune related factors and cells before and after neoadjuvant chemotherapy and camrelizumab use, as well as the responsiveness of different molecular subtypes of endometrial cancer to neoadjuvant therapy,.
03

Conditions studied

  • Endometrioid Endometrial Cancer

Keywords

  • Neoadjuvant chemotherapy
  • PD-1 inhibitor (Camrelizumab)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Endometrial cancer initially diagnosed as stage III non-operable resectable, stage IV (FIGO, 2009 criteria) after imaging evaluation
  2. confirmed endometrial cancer that looks like endometrial carcinoma
  3. Patient age ≥18 years and ≤75 years old
  4. status score of 0-1
  5. tolerate surgery and systemic therapy
  6. Laboratory tests: WBC ≥3.5×109/L, NEU ≥1.5×109/L, ≥80×109/L, serum ≥80×109/L, serum ≥80×109/L, serum ≥80×109/L, serum ≥80×109/L.

    ×109/L, serum ≤1.5 times the high limit of normal value, transaminase ≤1.5 times the high limit of normal value, BUN ≤1.5 times the high limit of normal value.

    1.5 times of the high limit of normal value, BUN, Cr≤normal value;

  7. Able to follow up and good compliance;
  8. Able to sign the form, including compliance with the requirements and restrictions listed in the informed consent form and the program.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with an active, known, or suspected disease, or a history of an autoimmune disease, except for: vitiligo, alopecia areata, Graves' disease, psoriasis, or eczema that has not required systemic therapy within the last 2 years, hypothyroidism that is asymptomatic or requires only stable doses of hormone replacement therapy (due to autoimmune thyroiditis), type 1 diabetes that requires only stable doses of insulin replacement therapy, asthma that subsides completely in childhood and does not require intervention in adulthood, or diseases that do not recur in the absence of external triggers;
  2. Prior treatment with , including, but not limited to, other anti-PD-1, anti-PD-L1 antibodies, CTLA-4 antibodies, or any treatment directed against immune co-stimulators (e.g., antibodies directed against ICOS, 0, CD137, GITR, OX40 targets, etc.) that target any mechanism of immune action against tumors;
  3. Known to any component and/or any of the trial regimen;
  4. drugs or systemic for immunosuppression (>10 mg/day of prednisone or other equivalent) within 2 weeks prior to trial dosing; topical, ophthalmic, intra-articular, intranasal, and inhaled corticosteroids are permitted;
  5. Received herbs with antitumor effects or drugs with immunomodulatory effects (e.g., thymidine, interferon, interleukin-2) within 2 weeks prior to the trial;
  6. Active systemic infection requiring systemic treatment;
  7. Serious infection within 4 weeks prior to the first dose, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia;
  8. Patients with untreated chronic , or HBV carriers with chronic hepatitis B virus (HBV) DNA greater than 1,000 IU/mL, or patients with active . Inactive HBsAg carriers, treated hepatitis B patients with stable disease (HBV DNA \< 1000 IU/mL), and cured hepatitis C patients will be eligible for enrollment. HCV antibody-positive subjects will be eligible for the study only if they have a negative HCV RNA test;
  9. Known active tuberculosis (TB), patients with suspected active TB should undergo chest X-ray and sputum examination in conjunction with clinical signs and symptoms for exclusion;
  10. Immunodeficiency or (HIV antibody positive);
  11. Subjects with active inflammatory bowel disease or a history of such disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea). Subjects who are unable to swallow or who have malabsorption syndrome, uncontrolled nausea, vomiting, diarrhea, or other gastrointestinal disorders that severely interfere with drug intake and absorption;
  12. Known interstitial lung disease that is symptomatic or may interfere with detection or treatment of immune-associated pneumonia;
  13. Treatment with a live or attenuated vaccine administered within 4 weeks prior to the first trial dose, inactivated seasonal influenza virus vaccine is permitted;
  14. Patients who have received a prior bone marrow transplant or solid organ transplant;
  15. History of primary malignant tumor within the last 5 years;
  16. Subjects who have undergone major surgery (e.g., open abdomen, open chest, organ resection, etc.) and severe trauma within 28 days prior to the first dose of implantable infusion devices are permitted;
  17. Subjects with a history of gastrointestinal perforation, gastrointestinal fistula, or female genital fistula;
  18. Uncontrolled other co-morbidities, symptoms, or medical history, including: (1) Persons with one of the following cardiovascular diseases or cardiovascular risk factors: myocardial infarction, unstable angina pectoris, pulmonary embolism, acute/continuous myocardial ischemia, cerebral vascular accident, , theor other /required drug intervention arterial or venous thrombosis, embolism or cerebral ischemic events; symptoms of congestive heart failure ( class III or higher) within 6 months (ii) clinically significant bleeding symptoms or a history of significant bleeding characteristics, such as gastrointestinal bleeding, gastric ulcer bleeding, or vasculitis, within 1 month prior to the first dose; (iii) clinically active hemoptysis, active diverticulitis, abdominal abscess, and gastrointestinal obstruction; (iv) uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; (v) abnormalities of hepatic or renal development, or a history of surgery;
  19. Female patients who are pregnant or breastfeeding; women of childbearing age who refuse to accept measures during immunotherapy;
  20. Concurrent participation in other interventional clinical trials; participation in observational and non-interventional clinical trials is permitted;
  21. Any condition that, in the opinion of the Investigator, may result in risk in the receipt of the study drug or that would interfere with the evaluation of the safety of the study drug or the interpretation of the study results. In the judgment of the Investigator, it is unlikely that Patients who, in the judgment of the Investigator, are less likely to comply with the study steps, restrictions, and requirements shall not be permitted to participate in this study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant chemotherapy combined with PD-1 inhibitor in FIGO III/IV Endometrial carcinoma

    Patients with advanced endometrial cancer were enrolled for 2 or 3 cycles of neoadjuvant chemotherapy in combination with camrelizumab, with imaging to assess efficacy; intermittent subtractive surgery (transabdominal hysterectomy + bilateral adnexectomies + pelvic lymph node dissection + pelvic and abdominal tumors resections +/- para-abdominal aortic lymph node dissection) was performed in patients with complete remissions (CR)/partial remissions (PR), and continued with 3 or 4 cycles of neoadjuvant chemotherapy in combination with camrelizumab, ensuring that all patients receive a total of 6 cycles.

    Drug: Camrelizumab · Drug: Carboplatin · Drug: Paclitaxel · Procedure: Surgery

Interventions

  • Camrelizumab is administered at 200mg, q3w,intravenous infusion

  • AUC=5,q3w,intravenous infusion

  • 175 mg/m2,q3w,intravenous infusion, administered over 30min.

  • ProcedureSurgery

    Transabdominal hysterectomy + bilateral adnexectomy + pelvic lymph node dissection + pelvic-abdominal tumor resection +/- para-abdominal aortic lymph node dissection

06

What researchers measure

Primary outcomes

  1. Pathologic complete response

    Proportion of patients with no tumor cells on postoperative pathology and negative lymph node metastasis

    Time frame: At the end of the patient's treatment, up to 1 years.

Secondary outcomes

  1. Surgical complication rate

    intraoperative bleeding, vascular injuries, bladder injuries, rectal injuries, and ureteral injuries, as defined by the need for suture repair; occlusive nerve injuries, as defined by complete severance; and vascular injuries, as defined by the need to document the site of injury. Postoperative complications included: ureteral/bladder/rectal/vaginal fistula, internal hemorrhage, pelvic infection, lymphocyst, lymphatic fistula, lower extremity edema, lower extremity venous thrombosis, urinary retention, nerve injury, and bowel obstruction.

    Time frame: During and after the surgery, up to 2 years.

  2. Adverse Event

    Adverse Effects of immunotherapy and chemotherapy

    Time frame: during the treatment, up to 5 years.

  3. Remission rate (%) as assessed by RECIST 1.1 criteria

    Subjects were assessed for complete and partial remission rates according to RECIST 1.1 criteria

    Time frame: At the end of the patient's treatment, up to 1 years.

  4. Event-free survival (EFS)

    the time between the date of surgery to any documented tumor progression, recurrence, or death from any cause; the analysis of EFS includes the results of tumor evaluations during the study treatment and follow-up periods. If a patient had several indicators of PD or recurrence, the EFS analysis was performed using the indicator that appeared first; PD, recurrence, or death were considered to have reached the study endpoint; patients who were treated with other systemic or antitumor therapies directed at the target lesion of observation were also considered to be in PD; for patients who did not have PD, recurrence, or death at the end of the study, the time when the patient's failure to have a recurrence was last obtained was used as the time to censor the data.

    Time frame: Until the end of the 3-year follow-up period, up to 5 years.

  5. Overall survival (OS)

    the time from the start of the time from the date of enrollment to death from any cause

    Time frame: Until the end of the 3-year follow-up period, up to 5 years.

Other outcomes

  1. Change in Peripheral Lymphocyte Subsets

    Change from baseline in peripheral lymphocyte subsets (CD4+, CD8+, NK, and Treg) as assessed by single-cell sequencing of blood samples.

    Time frame: Baseline and at time of surgery (approximately 9-13 weeks after treatment initiation)

  2. Change in Tumor Cell PD-L1 Expression

    Change from baseline in tumor cell PD-L1 expression, assessed by immunohistochemistry using the Combined Positive Score (CPS) in paired pre-treatment biopsy and post-surgical specimens.

    Time frame: Baseline (pre-treatment biopsy) and at time of surgery (post-surgical specimen)

  3. Change in Tumor-Infiltrating Lymphocyte Density

    Change from baseline in CD8+ tumor-infiltrating lymphocyte (TIL) density and other immune-related biomarkers within the tumor microenvironment, assessed by immunohistochemistry in paired pre- and post-treatment specimens.

    Time frame: Baseline (pre-treatment biopsy) and at time of surgery (post-surgical specimen)

  4. Pathological Response by Molecular Subtype

    Pathological complete response (pCR) rate, defined as the absence of viable tumor cells in the resected specimen, evaluated according to molecular subtype (POLE-mutated, MMR-deficient, p53-abnormal, or NSMP).

    Time frame: At time of surgical resection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data collected during the trial will be made available upon reasonable request to the corresponding author.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available beginning 6 months after publication of the primary results and will remain available for 5 years.

Access criteria: Deidentified IPD and supporting documents will be made available to qualified researchers who provide a methodologically sound research proposal for independent scientific research. Requests should be directed to the corresponding author. Approval of the request and execution of a data sharing agreement will be required prior to data release.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

Of 107 non-industry phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 115. This study's planned 27 months is below that.

Counting every sponsor, half of 139 studies reached it within 55 months; a quarter within 37 and three quarters within 115.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2024
First posted
Aug 20, 2024
StartActual
Sep 1, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2032
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06561308
Lead sponsor
Women's Hospital School Of Medicine Zhejiang University
Collaborators
Xiangya Hospital of Central South University, Tongji Hospital, Qilu Hospital of Shandong University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Henan Provincial People's Hospital, Hunan Cancer Hospital, Zhejiang Cancer Hospital, First Affiliated Hospital of Wenzhou Medical University, Ningbo No. 1 Hospital, The First Affiliated Hospital of Zhengzhou University, Tianjin Medical University General Hospital
Responsible party
Sponsor
First posted
Aug 20, 2024
Start date
Sep 1, 2025
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2032 (estimated)
Last update
Jul 29, 2026

Study contacts

Yang Li, PHD
Contact
li_yang@zju.edu.cn
0086-0571-87061501
Hui Wang, PHD
principal investigator · Women's Hospital School Of Medicine Zhejiang University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Carboplatin · Paclitaxel

Start the discussion